Annual report pursuant to Section 13 and 15(d)

Notes Payable (Details)

v2.4.0.6
Notes Payable (Details) (USD $)
1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended
Jul. 31, 2012
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Jul. 31, 2012
Montaur Credit Facility [Member]
Dec. 31, 2012
Montaur Credit Facility [Member]
Jul. 31, 2012
Montaur Credit Facility [Member]
U.S. Prime Rate [Member]
Jul. 31, 2012
Montaur Credit Facility [Member]
Interest Rate Scenario Three [Member]
Dec. 31, 2012
Hercules Loan and Security Agreement [Member]
Dec. 31, 2011
Hercules Loan and Security Agreement [Member]
Dec. 31, 2011
Hercules Loan and Security Agreement [Member]
Navidia Debt Conversion Option [Member]
Dec. 31, 2011
Hercules Loan and Security Agreement [Member]
Hercules Debt Conversion Option [Member]
Dec. 31, 2012
Series GG Warrants [Member]
Dec. 31, 2011
Series GG Warrants [Member]
Dec. 31, 2011
Hercules Secured Term Promissory Note [Member]
Dec. 31, 2012
Hercules Secured Term Promissory Note [Member]
Dec. 31, 2011
Hercules Secured Term Promissory Note [Member]
Series GG Warrants [Member]
Notes Payable [Line Items]                                  
Maximum borrowing capacity         $ 50,000,000         $ 10,000,000         $ 10,000,000    
Current borrowing capacity         15,000,000                   7,000,000    
Debt instrument, spread on reference rate             6.75% 0.125%             6.75%    
Debt Instrument, minimum effective interest rate         10.00%                   10.00%    
Debt instrument, effective interest rate           10.125%                 10.00% 10.00%  
Debt instrument, maturity date                             Dec. 01, 2014    
Debt instrument, frequency of payment                             monthly    
Debt instrument, number of periodic payments                             30    
Amount potentially available on terms to be negotiated         15,000,000                        
Debt committed upon the approval of Lymphoseek on consistent terms 20,000,000                                
Amount drawn down during period           4,000,000                      
Principal amount due under credit facility           4,000,000                      
Interest expense related to debt           15,000     545,000 4,000              
Warrants, number of securities called by warrants                                 333,333
Warrants, exercise price   $ 0.68                     $ 2.1       $ 2.1
Warrants, expiration date                         Dec. 29, 2016       Dec. 31, 2016
Debt instrument, second advance amount                             3,000,000    
Debt conversion, original debt, amount convertible                     1,500,000 1,500,000          
Debt conversion, price per share                     $ 2.77 $ 2.77          
Beneficial conversion feature                             24,888    
Derivative liabilities      568,930                     520,478      
Debt issuance costs     593,000                       593,339    
Debt instrument, debt discount   202,287 0                       545,366    
Principal payments                 1,300,000                
Notes payable                 5,700,000                
Principal maturities in 2013                 2,700,000                
Principal maturities in 2014                 7,000,000                
Interest expense related to debt   $ 545,000 $ 4,000 $ 16,000